Study of Genistein in Reducing Side Effects of Superficial Bladder Cancer Treatment
| Status: | Recruiting |
|---|---|
| Conditions: | Cancer, Cancer, Bladder Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 11/16/2018 |
| Start Date: | May 19, 2017 |
| End Date: | May 2022 |
| Contact: | Omer Kucuk, MD |
| Email: | omer.kucuk@emory.edu |
| Phone: | 404-778-4538 |
Phase II Randomized Placebo-Controlled Clinical Trial of Genistein in Reducing the Toxicity and Improving the Efficacy of Intravesical Therapy
Patients with non-invasive bladder cancer are often treated with intravesical therapy in
order to prevent the recurrence of bladder cancer. Intravesical therapy can cause many lower
urinary tract symptoms, which can limit the dose of therapy and therefore efficacy of
treatment. There have been a number of studies that suggest a chemical found in soy beans may
be able to help with these side effects. This chemical is called genistein and can be
extracted and given to study subjects in pill form. In this study, the investigators would
like to have patients placed into two different groups. One group would take genistein and
the other group would take a placebo, a sugar pill that looks like the genistein pill. In
doing this study the investigators hope to explore the findings from other studies to see if
lower urinary tract symptoms are reduced and to see if recurrence rates for patients are
affected by genistein. The study would take about four and a half months total.
order to prevent the recurrence of bladder cancer. Intravesical therapy can cause many lower
urinary tract symptoms, which can limit the dose of therapy and therefore efficacy of
treatment. There have been a number of studies that suggest a chemical found in soy beans may
be able to help with these side effects. This chemical is called genistein and can be
extracted and given to study subjects in pill form. In this study, the investigators would
like to have patients placed into two different groups. One group would take genistein and
the other group would take a placebo, a sugar pill that looks like the genistein pill. In
doing this study the investigators hope to explore the findings from other studies to see if
lower urinary tract symptoms are reduced and to see if recurrence rates for patients are
affected by genistein. The study would take about four and a half months total.
Patients who are treated with bacillus Calmette-Guerin (BCG) intravesical therapy for
non-muscle invasive (TaT1) Tis superficial bladder cancer often develop adverse effects
(urinary tract symptoms) which limit the dose (and therefore the efficacy) of therapy and
result in poor quality of life. Genistein is a nutritional supplement with anti-inflammatory
properties which might help alleviate adverse effects of intravesical therapy that are due to
inflammation. Additionally, genistein also has anti-tumor and immunopotentiating properties
and has been shown to have no known side effects. Our hypothesis is that genistein given
together with BCG intravesical therapy will reduce its adverse effects and improve the
efficacy of therapy. Patients (N=88) scheduled for intravesical therapy will be randomly
assigned to take 30 mg tablets PO TID of genistein supplement (N=44) or placebo (N=44) during
therapy and one month post therapy.
non-muscle invasive (TaT1) Tis superficial bladder cancer often develop adverse effects
(urinary tract symptoms) which limit the dose (and therefore the efficacy) of therapy and
result in poor quality of life. Genistein is a nutritional supplement with anti-inflammatory
properties which might help alleviate adverse effects of intravesical therapy that are due to
inflammation. Additionally, genistein also has anti-tumor and immunopotentiating properties
and has been shown to have no known side effects. Our hypothesis is that genistein given
together with BCG intravesical therapy will reduce its adverse effects and improve the
efficacy of therapy. Patients (N=88) scheduled for intravesical therapy will be randomly
assigned to take 30 mg tablets PO TID of genistein supplement (N=44) or placebo (N=44) during
therapy and one month post therapy.
Inclusion Criteria:
1. Male or female gender
2. 18 years or older
3. Diagnosis of superficial bladder cancer
4. Scheduled for induction BCG intravesical therapy
5. Willing and able to give blood sample
6. Willing and able to fill out a pill diary to ensure compliance
7. Willing and able to sign informed consent
8. Birth control is not required for this study!
Exclusion Criteria:
1. Patients who are pregnant
2. Diagnosis of muscle-invasive bladder cancer
3. Unwillingness to follow study protocol and compliance procedures
4. HIV positive or immunocompromised
5. Receiving concurrent immunotherapy or chemotherapy
6. Presence of concurrent second cancer (active, not history)
We found this trial at
2
sites
Click here to add this to my saved trials
Click here to add this to my saved trials